Devroe Eric 4
4 · Acrivon Therapeutics, Inc. · Filed May 21, 2024
Insider Transaction Report
Form 4
Devroe Eric
Chief Operating Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2024-05-17−10,000→ 86,615 totalExercise: $1.04Exp: 2031-01-13→ Common Stock (10,000 underlying) - Exercise/Conversion
Common Stock
2024-05-17$1.04/sh+10,000$10,400→ 69,097 total
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to the option vested on October 5, 2021, and the remaining shares subject to the option vested or shall vest in 12 equal quarterly installments thereafter, in each case subject to the Reporting Person's continuous service through each such vesting date.